Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) saw strong trading volume on Friday . 1,871,731 shares were traded during mid-day trading, a decline of 21% from the previous session’s volume of 2,354,674 shares.The stock last traded at $6.03 and had previously closed at $6.01.

A number of equities research analysts have issued reports on the stock. Griffin Securities reissued a “buy” rating and issued a $21.00 price target on shares of Ziopharm Oncology in a report on Tuesday, June 7th. Raymond James Financial Inc. assumed coverage on shares of Ziopharm Oncology in a report on Thursday, June 2nd. They issued a “market perform” rating on the stock. Vetr raised shares of Ziopharm Oncology from a “buy” rating to a “strong-buy” rating and set a $9.76 price target on the stock in a report on Monday, April 25th. Mizuho raised their price target on shares of Ziopharm Oncology from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Wednesday, May 11th. Finally, Zacks Investment Research raised shares of Ziopharm Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $11.07.

The company has a 50 day moving average of $6.48 and a 200-day moving average of $7.07. The company’s market capitalization is $786.50 million.

Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.01. During the same quarter last year, the firm posted ($0.69) earnings per share. The company had revenue of $1.97 million for the quarter, compared to the consensus estimate of $1.89 million. The firm’s quarterly revenue was up 623.9% compared to the same quarter last year. Equities analysts predict that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current year.

A number of large investors have added to or reduced their stakes in the stock. California State Teachers Retirement System increased its stake in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares during the last quarter. Swiss National Bank increased its stake in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the last quarter. Wells Fargo & Company MN increased its stake in Ziopharm Oncology by 18.4% in the fourth quarter. Wells Fargo & Company MN now owns 168,616 shares of the biotechnology company’s stock worth $1,402,000 after buying an additional 26,233 shares during the last quarter. Morgan Stanley increased its stake in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the last quarter. Finally, California Public Employees Retirement System increased its stake in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.